Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 536538, 17 pages
http://dx.doi.org/10.4061/2010/536538
Review Article

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies

Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Westgate Road, Newcastle upon Tyne, Newcastle NE5 5PL, UK

Received 15 April 2010; Revised 6 July 2010; Accepted 4 August 2010

Academic Editor: Lucilla Parnetti

Copyright © 2010 Elizabeta B. Mukaetova-Ladinska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Knapp, M. Prince, E. Albanese et al., “A report into the prevalence and cost of dementia’ Alzheimers society,” London, UK, 2007.
  2. R. Barber, A. Panikkar, and I. G. McKeith, “Dementia with Lewy bodies: diagnosis and management,” International Journal of Geriatric Psychiatry, vol. 16, no. 1, pp. S12–S18, 2001. View at Google Scholar
  3. I. G. McKeith, D. Galasko, K. Kosaka et al., “Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop,” Neurology, vol. 47, no. 5, pp. 1113–1124, 1996. View at Google Scholar
  4. I. McKeith, J. Mintzer, D. Aarsland et al., “International psychogeriatric association expert meeting on DLB (Dementia with Lewy bodies),” Lancet Neurology, vol. 3, pp. 19–28, 2004. View at Google Scholar
  5. I. G. McKeith, D. W. Dickson, J. Lowe et al., “Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium,” Neurology, vol. 65, no. 12, pp. 1863–1872, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. J. Verghese, H. A. Crystal, D. W. Dickson, and R. B. Lipton, “Validity of clinical criteria for the diagnosis of dementia with Lewy bodies,” Neurology, vol. 53, no. 9, pp. 1974–1982, 1999. View at Google Scholar
  7. I. G. McKeith, C. G. Ballard, R. H. Perry et al., “Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies,” Neurology, vol. 54, no. 5, pp. 1050–1058, 2000. View at Google Scholar
  8. P. Tiraboschi, D. P. Salmon, L. A. Hansen, R. C. Hofstetter, L. J. Thal, and J. Corey-Bloom, “What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?” Brain, vol. 129, no. 3, pp. 729–735, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. K. A. Jellinger, “In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution,” Neurology, vol. 70, no. 5, pp. 407–408, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. E. Noe, K. Marder, K. L. Bell, D. M. Jacobs, J. J. Manly, and Y. Stern, “Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia,” Movement Disorders, vol. 19, no. 1, pp. 60–67, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. J. L. W. Bosboom and E. Wolters, “Psychotic symptoms in Parkinson's disease: pathophysiology and management,” Expert Opinion on Drug Safety, vol. 3, no. 3, pp. 209–220, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. E. J. Burton, R. Barber, E. B. Mukaetova-Ladinska et al., “Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis,” Brain, vol. 132, no. 1, pp. 195–203, 2009. View at Publisher · View at Google Scholar · View at PubMed
  13. K. Lobotesis, J. D. Fenwick, A. Phipps et al., “Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD,” Neurology, vol. 56, no. 5, pp. 643–649, 2001. View at Google Scholar
  14. S. Shimizu, H. Hanyu, H. Kanetaka, T. Iwamoto, K. Koizumi, and K. Abe, “Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT,” Dementia and Geriatric Cognitive Disorders, vol. 20, no. 1, pp. 25–30, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. P. M. Kemp, S. A. Hoffmann, L. Tossici-Bolt, J. S. Fleming, and C. Holmes, “Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies,” Nuclear Medicine Communications, vol. 28, no. 6, pp. 451–456, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. G. Kägi, K. P. Bhatia, and E. Tolosa, “The role of DAT-SPECT in movement disorders,” Journal of Neurology Neurosurgery and Psychiatry, vol. 81, pp. 5–12, 2010. View at Google Scholar
  17. P. Edison, H. A. Archer, R. Hinz et al., “Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study,” Neurology, vol. 68, no. 7, pp. 501–508, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. W. Maetzler, I. Liepelt, M. Reimold et al., “Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics,” Neurobiology of Disease, vol. 34, no. 1, pp. 107–112, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. J. Taki, M. Yoshita, M. Yamada, and N. Tonami, “Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease,” Annals of Nuclear Medicine, vol. 18, no. 6, pp. 453–461, 2004. View at Google Scholar
  20. M. Yoshita, J. Taki, K. Yokoyama et al., “Value of I123-MIBG radioactivity in the differential diagnosis of DLB from AD,” Neurology, vol. 66, no. 12, pp. 1850–1854, 2006. View at Publisher · View at Google Scholar · View at PubMed
  21. S. L. Schmidt, P. L. Correa, J. C. Tolentino et al., “Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult,” Clinical Nuclear Medicine, vol. 33, no. 6, pp. 398–401, 2008. View at Publisher · View at Google Scholar · View at PubMed
  22. F. Novellino, A. Bagnato, M. Salsone et al., “Myocardial 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD,” Neurobiology of Aging, vol. 31, no. 11, pp. 1903–1911, 2010. View at Publisher · View at Google Scholar · View at PubMed
  23. A. F. Jacobson, R. Senior, M. D. Cerqueira et al., “Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study,” Journal of the American College of Cardiology, vol. 55, no. 20, pp. 2212–2221, 2010. View at Publisher · View at Google Scholar · View at PubMed
  24. H. Ueshima, A. Sekikawa, K. Miura et al., “Cardiovascular disease and risk factors in Asia: a selected review,” Circulation, vol. 118, no. 25, pp. 2702–2709, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. J. H. Xuereb, C. Brayne, C. Dufouil et al., “Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders,” Annals of the New York Academy of Sciences, vol. 903, pp. 490–496, 2000. View at Google Scholar
  26. F. E. Matthews, C. Jagger, L. L. Miller, and C. Brayne, “Education differences in life expectancy with cognitive impairment,” Journals of Gerontology A, vol. 64, no. 1, pp. 125–131, 2009. View at Publisher · View at Google Scholar · View at PubMed
  27. C. G. Ballard, R. Jacoby, T. Del Ser et al., “Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies,” American Journal of Psychiatry, vol. 161, no. 5, pp. 843–849, 2004. View at Publisher · View at Google Scholar
  28. J. M. Hamilton, D. P. Salmon, D. Galasko et al., “Visuospatial deficits predict rate of cognitive decline in autopsy verified dementia with Lewy bodies,” Neuropsychology, vol. 22, no. 6, pp. 729–737, 2008. View at Publisher · View at Google Scholar · View at PubMed
  29. W. Samuel, M. Alford, C. R. Hofstetter, and L. Hansen, “Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density,” Journal of Neuropathology and Experimental Neurology, vol. 56, no. 5, pp. 499–508, 1997. View at Google Scholar
  30. R. L. Hamilton, “Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry,” Brain Pathology, vol. 10, no. 3, pp. 378–384, 2000. View at Google Scholar
  31. O. L. Lopez, J. T. Becker, R. A. Sweet, F. J. Martin-Sanchez, and R. L. Hamilton, “Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease,” Neurology, vol. 67, no. 4, pp. 660–665, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. J. M. Olichney, D. Galasko, D. P. Salmon et al., “Cognitive decline is faster in Lewy body variant than in Alzheimer's disease,” Neurology, vol. 51, no. 2, pp. 351–357, 1998. View at Google Scholar
  33. M. Baker, “In biomarkers we trust?” Nature Biotechnology, vol. 23, no. 3, pp. 297–304, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. D. E. Shapiro, “The interpretation of diagnostic tests,” Statistical Methods in Medical Research, vol. 8, no. 2, pp. 113–134, 1999. View at Publisher · View at Google Scholar
  35. P. Davidsson, L. Paulson, C. Hesse, K. Blennow, and C. L. Nilsson, “Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electophoresis approach prior to mass spectrometry,” Proteomics, vol. 1, no. 3, pp. 444–452, 2001. View at Google Scholar
  36. E. B. Mukaetova-Ladinska and I. G. McKeith, “Pathophysiology of synuclein aggregation in Lewy body disease,” Mechanisms of Ageing and Development, vol. 127, no. 2, pp. 188–202, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. R. Raghavan, L. Kruijff, M. D. Sterrenburg, B. B. Rogers, C. L. Hladik, and C. L. White III, “Alpha-synuclein expression in the developing human brain,” Pediatric and Developmental Pathology, vol. 7, no. 5, pp. 506–516, 2004. View at Google Scholar
  38. H. Fujiwara, M. Hasegawa, N. Dohmae et al., “α-synuclein is phosphorylated in synucleinopathy lesions,” Nature Cell Biology, vol. 4, no. 2, pp. 160–164, 2002. View at Publisher · View at Google Scholar · View at PubMed
  39. K. Obi, H. Akiyama, H. Kondo et al., “Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies,” Experimental Neurology, vol. 210, no. 2, pp. 409–420, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. D. W. Tsuang, L. DiGiacomo, and T. D. Bird, “Familial occurrence of dementia with Lewy bodies,” American Journal of Geriatric Psychiatry, vol. 12, no. 2, pp. 179–188, 2004. View at Publisher · View at Google Scholar
  41. A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson's disease,” Science, vol. 302, no. 5646, p. 841, 2003. View at Publisher · View at Google Scholar · View at PubMed
  42. R. Borghi, R. Marchese, A. Negro et al., “Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects,” Neuroscience Letters, vol. 287, no. 1, pp. 65–67, 2000. View at Publisher · View at Google Scholar
  43. O. M. A. El-Agnaf and G. B. Irvine, “Aggregation and neurotoxicity of α-synuclein and related peptides,” Biochemical Society Transactions, vol. 30, no. 4, pp. 559–565, 2002. View at Publisher · View at Google Scholar
  44. C. Ballard, E. L. Jones, E. Londos, L. Minthon, P. Francis, and D. Aarsland, “α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies,” International Psychogeriatrics, vol. 22, pp. 321–327, 2010. View at Publisher · View at Google Scholar · View at PubMed
  45. E. B. Mukaetova-Ladinska, J. Milne, A. Andras et al., “Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes,” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 1, pp. 32–42, 2008. View at Publisher · View at Google Scholar · View at PubMed
  46. M. Noguchi-Shinohara, T. Tokuda, M. Yoshita et al., “CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease,” Brain Research, vol. 1251, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. E. Gómez-Tortosa, K. Newell, M. C. Irizarry, M. Albert, J. H. Growdon, and B. T. Hyman, “Clinical and quantitative pathologic correlates of dementia with Lewy bodies,” Neurology, vol. 53, no. 6, pp. 1284–1291, 1999. View at Google Scholar
  48. P. E. Spies, R. J. F. Melis, M. J. C. Sjögren, M. G. M. O. Rikkert, and M. M. Verbeek, “Cerebrospinal fluid α-synuclein does not discriminate between dementia disorders,” Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 363–369, 2009. View at Publisher · View at Google Scholar · View at PubMed
  49. A. Öhrfelt, P. Grognet, N. Andreasen et al., “Cerebrospinal fluid α-synuclein in neurodegenerative disorders-A marker of synapse loss?” Neuroscience Letters, vol. 450, no. 3, pp. 332–335, 2009. View at Publisher · View at Google Scholar · View at PubMed
  50. E.B. Mukaetova-Ladinska, F. Garcia-Siera, J. Hurt et al., “Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease,” American Journal of Pathology, vol. 157, no. 2, pp. 623–636, 2000. View at Google Scholar
  51. B. Mollenhauer, V. Cullen, I. Kahn et al., “Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration,” Experimental Neurology, vol. 213, no. 2, pp. 315–325, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. K. Kasuga, T. Tokutake, A. Ishikawa et al., “Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 6, pp. 608–610, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. F. Sironi, L. Trotta, A. Antonini et al., “α-synuclein multiplication analysis in Italian familial Parkinson disease,” Parkinsonism and Related Disorders, vol. 16, no. 3, pp. 228–231, 2010. View at Publisher · View at Google Scholar · View at PubMed
  54. H. Arai, M. Terajima, M. Miura et al., “Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease,” Annals of Neurology, vol. 38, no. 4, pp. 649–652, 1995. View at Publisher · View at Google Scholar · View at PubMed
  55. L. Parnetti, A. Lanari, S. Amici, V. Gallai, E. Vanmechelen, and F. Hulstaert, “CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies,” Neurological Sciences, vol. 22, no. 1, pp. 77–78, 2001. View at Publisher · View at Google Scholar
  56. C. M. Clark, S. Xie, J. Chittams et al., “Cerebrospinal fluid tau and β-amyloid,” Archives of Neurology, vol. 60, no. 12, pp. 1696–1702, 2003. View at Publisher · View at Google Scholar · View at PubMed
  57. H. Hampel, K. Buerger, R. Zinkowski et al., “Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study,” Archives of General Psychiatry, vol. 61, no. 1, pp. 95–102, 2004. View at Publisher · View at Google Scholar · View at PubMed
  58. L. Parnetti, P. Tiraboschi, A. Lanari et al., “Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies,” Biological Psychiatry, vol. 64, no. 10, pp. 850–855, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. H. Vanderstichele, K. De Vreese, K. Blennow et al., “Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 12, pp. 1472–1480, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. G. Simic, M. Boban, H. Sarac et al., “CSF tau proteins in evaluation of patients with suspected dementia,” in New Trends in Alzheimer and Parkinson Related Disorders, ADPD 2007, Medimond, Salzburg, Austria, 2007. View at Google Scholar
  61. K. Koopman, N. Le Bastard, J.-J. Martin, G. Nagels, P. P. De Deyn, and S. Engelborghs, “Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P,” Neurochemistry International, vol. 55, no. 4, pp. 214–218, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. N. Mattsson, H. Zetterberg, O. Hansson et al. et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” JAMA, vol. 302, no. 4, pp. 385–393, 2009. View at Google Scholar
  63. P. E. Spies, J. M. Sjögren, B. P. Kremer, F. R. Verhey, M. G. Rikkert, and M. M. Verbeek, “The cerebrospinal fluid amyloid beta (42/40) ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia,” Current Alzheimer Research, vol. 7, no. 5, pp. 470–476, 2010. View at Google Scholar
  64. M. Bibl, B. Mollenhauer, H. Esselmann et al., “CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia,” Brain, vol. 129, no. 5, pp. 1177–1187, 2006. View at Publisher · View at Google Scholar · View at PubMed
  65. M. Bibl, B. Mollenhauer, H. Esselmann et al., “CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies,” Journal of Neural Transmission, vol. 113, no. 11, pp. 1771–1778, 2006. View at Publisher · View at Google Scholar · View at PubMed
  66. K. Wada-Isoe, K. Michio, K. Imamura et al., “Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis,” Journal of Neural Transmission, vol. 114, no. 12, pp. 1579–1583, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. K. Wada-Isoe, M. Kitayama, K. Nakaso, and K. Nakashima, “Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study,” Journal of the Neurological Sciences, vol. 260, no. 1-2, pp. 33–37, 2007. View at Publisher · View at Google Scholar · View at PubMed
  68. F. Boström, O. Hansson, L. Gerhardsson et al., “CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies,” Neurobiology of Aging, vol. 30, no. 8, pp. 1265–1271, 2009. View at Publisher · View at Google Scholar · View at PubMed
  69. J. A. Molina, J. C. Leza, S. Ortiz et al., “Cerebrospinal fluid and plasma concentrations of nitric oxide metabolites are increased in dementia with Lewy bodies,” Neuroscience Letters, vol. 333, no. 2, pp. 151–153, 2002. View at Publisher · View at Google Scholar
  70. J. A. Molina, P. Gómez, C. Vargas et al., “Neurotransmitter amino acid in cerebrospinal fluid of patients with dementia with Lewy bodies,” Journal of Neural Transmission, vol. 112, no. 4, pp. 557–563, 2005. View at Publisher · View at Google Scholar · View at PubMed
  71. K. Schultz, S. Wiehager, K. Nilsson et al., “Reduced CSF CART in dementia with Lewy bodies,” Neuroscience Letters, vol. 453, no. 2, pp. 104–106, 2009. View at Publisher · View at Google Scholar · View at PubMed
  72. K. Schultz, K. Nilsson, J. E. Nielsen et al., “Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors,” European Journal of Neurology, vol. 17, no. 3, pp. 456–460, 2010. View at Publisher · View at Google Scholar · View at PubMed
  73. A. Alimonti, B. Bocca, A. Pino, F. Ruggieri, G. Forte, and G. Sancesario, “Elemental profile of cerebrospinal fluid in patients with Parkinson's disease,” Journal of Trace Elements in Medicine and Biology, vol. 21, no. 4, pp. 234–241, 2007. View at Publisher · View at Google Scholar · View at PubMed
  74. H. Asai, M. Hirano, Y. Furiya et al., “Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease,” Clinical Neurology and Neurosurgery, vol. 111, no. 4, pp. 341–344, 2009. View at Publisher · View at Google Scholar · View at PubMed
  75. M. Bibl, H. Esselmann, B. Mollenhauer et al., “Blood-based neurochemical diagnosis of vascular dementia: a pilot study,” Journal of Neurochemistry, vol. 103, no. 2, pp. 467–474, 2007. View at Publisher · View at Google Scholar · View at PubMed
  76. Y. Compta, M. J. Martí, N. Ibarretxe-Bilbao et al., “Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease,” Movement Disorders, vol. 24, no. 15, pp. 2203–2210, 2009. View at Publisher · View at Google Scholar · View at PubMed
  77. G. Lunardi, S. Galati, D. Tropepi et al., “Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 5, pp. 383–389, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. Z. Salehi and F. Mashayekhi, “Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease,” Journal of Clinical Neuroscience, vol. 16, no. 1, pp. 90–93, 2009. View at Publisher · View at Google Scholar · View at PubMed
  79. F. Abdi, J. F. Quinn, J. Jankovic et al., “Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders,” Journal of Alzheimer's Disease, vol. 9, no. 3, pp. 293–348, 2006. View at Google Scholar
  80. M. Basso, S. Giraudo, D. Corpillo, B. Bergamasco, L. Lopiano, and M. Fasano, “Proteome analysis of human substantia nigra in Parkinson's disease,” Proteomics, vol. 4, no. 12, pp. 3943–3952, 2004. View at Publisher · View at Google Scholar · View at PubMed
  81. P. Davidsson, A. Westman-Brinkmalm, C. L. Nilsson et al., “Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients,” NeuroReport, vol. 13, no. 5, pp. 611–615, 2002. View at Google Scholar
  82. G. N. Yin, H. W. Lee, J.-Y. Cho, and K. Suk, “Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases,” Brain Research, vol. 1265, pp. 158–170, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. T. Tokuda, S. A. Salem, D. Allsop et al., “Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease,” Biochemical and Biophysical Research Communications, vol. 349, no. 1, pp. 162–166, 2006. View at Publisher · View at Google Scholar · View at PubMed
  84. G. B. Irvine, O. M. El-Agnaf, G. M. Shankar, and D. M. Walsh, “Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases,” Molecular Medicine, vol. 14, no. 7-8, pp. 451–464, 2008. View at Publisher · View at Google Scholar · View at PubMed
  85. K. Ono, M. Noguchi-Shinohara, M. Yoshita, H. Naiki, and M. Yamada, “Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitro,” Experimental Neurology, vol. 203, no. 2, pp. 579–583, 2007. View at Publisher · View at Google Scholar · View at PubMed
  86. E. B. Mukaetova-Ladinska, J. Hurt, R. Jakes, J. Xuereb, W. G. Honer, and C. M. Wischik, “α-synuclein inclusions in Alzheimer and Lewy body diseases,” Journal of Neuropathology and Experimental Neurology, vol. 59, no. 5, pp. 408–417, 2000. View at Google Scholar
  87. C. R. Harrington, E. B. Mukaetova-Ladinska, R. Hills et al., “Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 13, pp. 5842–5846, 1991. View at Publisher · View at Google Scholar
  88. C. Yao, A. J. Williams, A. K. Ottens et al., “Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats,” Brain Injury, vol. 22, no. 10, pp. 723–732, 2008. View at Publisher · View at Google Scholar · View at PubMed
  89. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging, “Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease,” Neurobiology of Aging, vol. 19, pp. 109–116, 1998. View at Google Scholar
  90. K. Buerger, R. Zinkowski, S. J. Teipel et al., “Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231,” Archives of Neurology, vol. 59, no. 8, pp. 1267–1272, 2002. View at Publisher · View at Google Scholar
  91. D. De Jong, R. W. M. M. Jansen, Y. A. L. Pijnenburg et al., “CSF neurofilament proteins in the differential diagnosis of dementia,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 9, pp. 936–938, 2007. View at Publisher · View at Google Scholar · View at PubMed
  92. H. Arai, Y.-I. Morikawa, M. Higuchi et al., “Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 262–264, 1997. View at Publisher · View at Google Scholar
  93. S. Engelborghs, K. De Vreese, T. Van de Casteele et al., “Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia,” Neurobiology of Aging, vol. 29, no. 8, pp. 1143–1159, 2008. View at Publisher · View at Google Scholar · View at PubMed
  94. M. Brazzelli, E. Capitani, S. Della Sala, H. Spinnler, and M. Zuffi, “A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment,” Journal of Neurology Neurosurgery and Psychiatry, vol. 57, no. 12, pp. 1510–1517, 1994. View at Google Scholar
  95. O. Katsuse, E. Iseki, W. Marui, and K. Kosaka, “Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies,” Journal of the Neurological Sciences, vol. 211, no. 1-2, pp. 29–35, 2003. View at Publisher · View at Google Scholar
  96. G. B. Stokin and L. S. B. Goldstein, “Axonal transport and Alzheimer's disease,” Annual Review of Biochemistry, vol. 75, pp. 607–627, 2006. View at Publisher · View at Google Scholar · View at PubMed
  97. M. Oinas, T. Polvikoski, R. Sulkava et al., “Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study,” Journal of Alzheimer's Disease, vol. 18, no. 3, pp. 677–689, 2009. View at Publisher · View at Google Scholar · View at PubMed
  98. D. J. Burn, E. K. Perry, and J. T. O’Brien, “Dementia with Lewy bodies,” in Neurobiology of Mental Illness, D. S. Charney and E. J. Nestler, Eds., pp. 1010–1031, Oxford University Press, New York, NY, USA, 3rd edition, 2009. View at Google Scholar
  99. T. Tapiola, I. Alafuzoff, S.-K. Herukka et al., “Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain,” Archives of Neurology, vol. 66, no. 3, pp. 382–389, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. K. Buerger, M. Ewers, T. Pirttilä et al., “CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease,” Brain, vol. 129, no. 11, pp. 3035–3041, 2006. View at Publisher · View at Google Scholar · View at PubMed
  101. S. Engelborghs, K. Sleegers, P. Cras et al., “No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease,” Brain, vol. 130, no. 9, pp. 2320–2326, 2007. View at Publisher · View at Google Scholar · View at PubMed
  102. K. Buerger, I. Alafuzoff, M. Ewers, T. Pirttilä, R. Zinkowski, and H. Hampel, “No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease,” Brain, vol. 130, no. 10, pp. e82.1–e82.2, 2007. View at Publisher · View at Google Scholar · View at PubMed
  103. R. Mena, P. Edwards, O. Perez-Olvera, and C. M. Wischik, “Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease,” Acta Neuropathologica, vol. 89, no. 1, pp. 50–56, 1995. View at Publisher · View at Google Scholar
  104. X. Huang, C. S. Atwood, M. A. Hartshorn et al., “The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction,” Biochemistry, vol. 38, no. 24, pp. 7609–7616, 1999. View at Publisher · View at Google Scholar · View at PubMed
  105. L. K. Clinton, M. Blurton-Jones, K. Myczek, J. Q. Trojanowski, and F. M. LaFerla, “Synergistic interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline,” Journal of Neuroscience, vol. 30, no. 21, pp. 7281–7289, 2010. View at Publisher · View at Google Scholar · View at PubMed
  106. J. C. Hanson and C. F. Lippa, “Lewy body dementia,” International Review of Neurobiology, vol. 84, pp. 215–228, 2009. View at Publisher · View at Google Scholar
  107. W. Maetzler, B. Schmid, M. Synofzik et al., “The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease,” Journal of Alzheimer's Disease, vol. 19, no. 3, pp. 937–942, 2010. View at Publisher · View at Google Scholar · View at PubMed
  108. B. Tizon, E. M. Ribe, W. Mi, C. M. Troy, and E. Levy, “Cystatin C protects neuronal cells from amyloid-β-induced toxicity,” Journal of Alzheimer's Disease, vol. 19, no. 3, pp. 885–894, 2010. View at Publisher · View at Google Scholar · View at PubMed
  109. R. A. Armstrong and N. J. Cairns, “Size frequency distribution of the β-amyloid (aβ) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology,” Neurological Sciences, vol. 30, no. 6, pp. 471–477, 2009. View at Publisher · View at Google Scholar · View at PubMed
  110. H. Vanderstichele, E. van Kerschaver, C. Hesse et al., “Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma,” Amyloid, vol. 7, no. 4, pp. 245–258, 2000. View at Google Scholar
  111. R. Schmidt, H. Schmidt, J. D. Curb, K. Masaki, L. R. White, and L. J. Launer, “Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study,” Annals of Neurology, vol. 52, no. 2, pp. 168–174, 2002. View at Publisher · View at Google Scholar · View at PubMed
  112. E. Gómez-Tortosa, I. Gonzalo, S. Fanjul et al., “Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease,” Archives of Neurology, vol. 60, no. 9, pp. 1218–1222, 2003. View at Publisher · View at Google Scholar · View at PubMed
  113. A. Ernst, K. Buerger, O. Hartmann et al., “Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation,” Journal of Neuroimmunology, vol. 221, no. 1-2, pp. 62–67, 2010. View at Publisher · View at Google Scholar · View at PubMed
  114. Z. Walker, D. C. Costa, R. W. H. Walker et al., “Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand,” Journal of Neurology Neurosurgery and Psychiatry, vol. 73, no. 2, pp. 134–140, 2002. View at Publisher · View at Google Scholar
  115. P. T. Francis and E. K. Perry, “Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies,” Movement Disorders, vol. 22, supplement 17, pp. S351–S357, 2007. View at Publisher · View at Google Scholar · View at PubMed
  116. H. Shimada, S. Hirano, H. Shinotoh et al., “Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET,” Neurology, vol. 73, no. 4, pp. 273–278, 2009. View at Publisher · View at Google Scholar · View at PubMed
  117. M. A. Piggott, C. G. Ballard, E. Rowan et al., “Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline,” Synapse, vol. 61, no. 11, pp. 903–911, 2007. View at Publisher · View at Google Scholar · View at PubMed
  118. J. C. Klein, C. Eggers, E. Kalbe et al., “Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo,” Neurology, vol. 74, no. 11, pp. 885–892, 2010. View at Publisher · View at Google Scholar · View at PubMed
  119. J. M. Souza, B. I. Giasson, Q. Chen, V. M.-Y. Lee, and H. Ischiropoulos, “Dityrosine cross-linking promotes formation of stable α-synuclein polymers: implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies,” Journal of Biological Chemistry, vol. 275, no. 24, pp. 18344–18349, 2000. View at Publisher · View at Google Scholar · View at PubMed
  120. C. F. Lippa, J. E. Duda, M. Grossman et al., “DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers,” Neurology, vol. 68, no. 11, pp. 812–819, 2007. View at Publisher · View at Google Scholar · View at PubMed
  121. M. A. Lovell, B. C. Lynn, S. Xiong, J. F. Quinn, J. Kaye, and W. R. Markesbery, “An aberrant protein complex in CSF as a biomarker of Alzheimer disease,” Neurology, vol. 70, no. 23, pp. 2212–2218, 2008. View at Publisher · View at Google Scholar · View at PubMed
  122. R. Fronczek, S. Overeem, S. Y. Y. Lee et al., “Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease,” Brain, vol. 131, no. 1, p. e88, 2008. View at Publisher · View at Google Scholar · View at PubMed
  123. K. Yasui, Y. Inoue, T. Kanbayashi, T. Nomura, M. Kusumi, and K. Nakashima, “CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration,” Journal of the Neurological Sciences, vol. 250, no. 1-2, pp. 120–123, 2006. View at Publisher · View at Google Scholar · View at PubMed
  124. E. Oestreicher, G. J. Sengstock, P. Riederer, C. W. Olanow, A. J. Dunn, and G. W. Arendash, “Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study,” Brain Research, vol. 660, no. 1, pp. 8–18, 1994. View at Publisher · View at Google Scholar
  125. J. Zhang, “Proteomics of human cerebrospinal fluid—the good, the bad, and the ugly,” Proteomics—Clinical Applications, vol. 1, no. 8, pp. 805–819, 2007. View at Publisher · View at Google Scholar